Compare Suncor Energy Inc. (SU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Suncor Energy Inc. trades at $70.8 (market cap $82.76B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Suncor Energy Inc. is far larger — about 4.9× Zimmer Biomet Holdings Inc's market cap, and Suncor Energy Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SU | ZBH | |
|---|---|---|
Market Cap | $82.76B | $16.95B |
Volume | 3,832,959 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $71.87 | $103.98 |
52-Week Low | $38.17 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | $89.29B | $24.02B |
Dividend Yield | 2.39% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $68.14, down slightly by 0.12% on the day. The stock exhibits a bullish technical trend, supported by strong fundamentals including a P/E of 13.46 and a net income margin of 14.7%. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Analyst consensus is strongly positive with 23 buy ratings and no sell recommendations. News highlights include asset divestments and a planned CEO transition to Peter Zebedee in 2027.
The outlook for SU is favorable, driven by robust cash flow, aggressive shareholder returns via buybacks and dividends, and a discounted valuation relative to peers. Key risks include commodity price volatility, operational disruptions from weather events, and execution of the leadership transition. The stock's current price near recent highs suggests momentum, but investors should weigh these factors against the strong fundamental backdrop.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
